Please login to the form below

Not currently logged in
Email:
Password:

cancer drug pricing

This page shows the latest cancer drug pricing news and features for those working in and with pharma, biotech and healthcare.

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing

EU starts investigation of Aspen's cancer drug pricing. Amid reports of price increases of several hundred per cent. ... Aspen Pharmacare is under investigation by the EU's competition authorities over its pricing of five cancer medicines, amid

Latest news

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    NICE U-turn on Opdivo for kidney cancer. BMS sways the watchdog with new data and a patient access scheme. ... happy that NICE has made this recommendation for patients with advanced kidney cancer and their families.”.

  • Italian pharma scandals prompts call for EU-wide pricing probe Italian pharma scandals prompts call for EU-wide pricing probe

    Italian pharma scandals prompts call for EU-wide pricing probe. Aspen fined 5.2m for threat to halt supply of cancer drugs if price hikes not accepted. ... a possible link between drug shortages and inflated pricing.

  • NICE turns down Keytruda for lung cancer in draft guidance NICE turns down Keytruda for lung cancer in draft guidance

    NICE turns down Keytruda for lung cancer in draft guidance. Says long-term benefits for advanced non-small cell lung cancer treatment not proven. ... NICE has been taking an increasingly tough stance on cancer drug pricing, holding out for steep

  • NICE backs five new drugs after discounts agreed NICE backs five new drugs after discounts agreed

    The UK drug-prescribing watchdog has backed the funding of five new drugs for cancer, high cholesterol and a chronic and debilitating skin disease. ... NICE had previously recommended the use of Tafinlar in melanoma in 2014 - before GlaxoSmithKline (GSK)

  • Tension expected as cancer market rises to $150bn-plus Tension expected as cancer market rises to $150bn-plus

    Last year, cancer drug sales were $107bn, an 11.5% increase on the $90bn recorded in the prior year, says the report, which has been published just as the American Society ... Debate on cancer drug pricing is expected to feature prominently alongside

More from news
Approximately 2 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics